Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer

Trial Profile

Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ziconotide (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms ZIDON
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 28 Mar 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2017.
    • 27 Nov 2015 Planned End Date changed from 1 Sep 2015 to 1 Jul 2017 according to the ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top